Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney

Kidney International

Volumn 55, Issue 1, 1999, Pages 29-62

  Dousa, Thomas P ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

cAMP; Collecting ducts; Extracellular signaling; Mesangial proliferative nephritis; Nephrogenic diabetes insipidus; PDE superfamily; Protein kinase A

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; VASOPRESSIN;

ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; KIDNEY COLLECTING TUBULE; KIDNEY DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032924098     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00233.x     Document Type: Article

References (232)

1. Robison GA, Butcher RW, Sutherland EW: Cyclic AMP. New York, Academic Press, 1971
2. Hardman JG: Other cyclic nucleolides, in Cyclic AMP, edited by Robison GA, Butcher RW, Sutherland EW, New York, Academic Press, 1971, pp 400-421
3. Coy MF: cGMP: The wayward child of the cyclic nucleotide family. Trends Neurosci 14:293-299, 1991
4. Robison GA, Butcher RW, Sutherland EW: Formation and metabolism of cyclic AMP, in Cyclic AMP, New York, Academic Press, 1971, pp 73-90
5. Sonnenburg WK, Beavo JA: Cyclic GMP and regulation of cyclic nucleotide hydrolysis. Adv Pharmacol 26:87-114, 1994
6. Barber R, Goka TJ, Butcher RW: Cyclic AMP turnover in intact tissue: Role of cyclic nucleotide phosphodiesterases, in Advances in Second Messenger and Phosphoprotein Research (vol 25), edited by Strada SJ, Hidaka H, New York, Raven Press, 1992, pp 1-11
7. Nicholson CD, Challiss RAJ, Shahid M: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes. Trends Pharmacol Sci 12:19-27, 1991
8. Houslay MD, Milligan G: Tailoring cAMP-signalling responses through isoform multiplicity. Trends Pharmacol Sci 22:217-224, 1997
9. Beavo JA, Reifsnyder DH: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150-155, 1990
10. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725-748, 1995
11. Mangantello VC, Murata T, Taira M, Belfrage P, Degerman E: Perspectives in biochemistry and biophysics: Diversity in cyclic nucleotide phosphodiesterase isozyme families. Arch Biochem Biophys 322:1-13, 1995
12. Conti M, Nemoz G, Sette C, Vincini E: Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrinol Rev 16:370-389, 1995
13. 1-2 add cell specific personalization to the control of the levels of the second messenger cyclic AMP. Adv Enzyme Regul 35:303-338, 1995
14. Manganiello VC, Elks ML: Regulation of particulate cAMP phosphodiesterase activity in 3T3-L1 adipocytes: The role of particulate phosphodiesterase in the antilipolytic action of insulin, in Mechanisms of Insulin Action, edited by Belfrage P, Donńr J, Strålfors P, Basle, Elsevier, 1986, pp 147-166
15. Dousa TP: Signaling role of PDE isozymes in pathobiology of glomerular mesangial cells. Studies in vitro and in vivo. Cell Biochem Biophys 29:19-34, 1998
16. Elks ML, Manganiello VC: Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3′,5′-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes. Endocrinology 115:1262-1268, 1984
17. Charbonneau H: Structure-function relationships among cyclic nucleotide phosphodiesterases, in Structure, Regulation and Drug Action, edited by Beavo J, Houslay MD, New York, John Wiley & Sons, 1990
18. Beavo J: Multiple phosphodiesterase isoenzymes: Background, nomenclature and implications, in Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action, edited by Beavo J, Houslay MD, New York, John Wiley & Sons, 1990
19. Loughney K, Ferguson K: Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods, in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 1-19
20. 2+/calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1), in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 65-80
21. Levitzki A: Targeting signal transduction for disease therapy. Curr Opin Cell Biol 8:239-244, 1996
22. Beavo JA, Hansen RS, Harrison SA, Hurwitz RL, Martins TJ, Mumby MC: Identification and properties of cyclic nucleotide phosphodiesterases. Mol Cell Endocrinol 28:387-410, 1982
23. Beavo JA, Conti M, Heaslip RJ: Multiple cyclic nucleotide phosphodiesterases. Mol Pharmacol 46:399-405, 1994
24. Newton RP, Salih SG, Khan JA: Cyclic CMP-specific phosphodiesterase activity, in Structure, Regulation and Drug Action, edited by Beavo J, Houslay MD, New York, John Wiley & Sons, 1990
25. A1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyl-transferase. Biochem J 308:673-681, 1995
26. Dent G, Giembycz MA: Interaction of PDE4 inhibitors and enzymes and cell functions, in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 111-126
27. Giembycz MA: Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol 43:2041-2051, 1992
28. 2+/calmodulin-stimulated cAMP phosphodiesterase. Biochem J 321:157-163, 1997
29. Yan C, Zhao AZ, Bentley JK, Beavo JA: The calmodulin- dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner. J Biol Chem 271:25699-25706, 1996
30. MacFarland RT, Zelus BD, Beavo JA: High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biochem Chem 266:136-142, 1991
31. Yang Q, Paskind M, Bolger G, Thompson WJ, Repaske DR, Cutler LS, Epstein PM: A novel cyclic GMP stimulated phosphodiesterase from rat brain. Biochem Biophys Res Commun 205: 1850-1858, 1994
32. Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K, Loughney K: Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3′,5′-cyclic nucleotide phosphodiesterase. Gene 191:89-95, 1997
33. Degerman E, Belfrage P, Manganiello VC: Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 272:6823-6826, 1997
34. Komas N, Movsesian M, Kedev S, Degerman E, Belfrage P, Manganiello VC: cGMP-inhibited phosphodiesterases (PDE3), in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 89-109
35. Shakur Y, Pryde JG, Houslay MD: Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram. Biochem J 292:677-686, 1993
36. 1H NMR and identification of the membrane association domain using chimeric constructs. J Biol Chem 271:16703-16711, 1996
37. O'Connell JC, McCallum JF, McPhee I, Wakefield J, Houslay ES, Wishart W, Bolger G, Frame M, Houslay MD: The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem J 318:255-262, 1996
38. Houslay MD, Scotland G, Erdogan S, Huston E, Mackenzie S, McCallum JF, McPhee I, Pooley L, Rena G, Ross A, Beard M, Peder A, Begg F, Wilkinson I, Yarwood S, Ackerman C, Houslay ES, Hoffman R, Engels P, Sullivan M, Bolger G: Intracellular targeting, interaction with Src homology 3 (SH3) domains and rolipram-detected conformational switches in cAMP-specific PDE4A phosphodiesterase. Biochem Soc Trans 25:374-381, 1997
39. Huston E, Lumb S, Russell A, Catterall C, Ross AH, Steele MR, Bolger GB, Perry MJ, Owens RJ, Houslay MD: Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3. Biochem J 328:549-558, 1997
40. Swinnen JV, Tsikalas KE, Conti M: Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from rat Sertoli cells. J Biol Chem 266:18370-18377, 1991
41. Conti M, Swinnen JV, Tsikalas KE, Jin S-LC: Structure and regulation of the rat high-affinity cyclic AMP phosphodiesterases, in Advances in Second Messenger and Phosphoprotein Research: The Biology of Cyclic Nucleotide Phosphodiesterases, edited by Strada SJ, Hidaka H, New York, Raven Press, 1992, pp 87-99
42. Lenhard JM, Kassel DB, Rocque WJ, Hamacher L, Holmes WD, Patel I, Hoffman C, Luther M: Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase. Biochem J 316:751-758, 1996
43. Müller T, Engels P, Fozard JR: Subtypes of the type 4 cAMP phosphodiesterases: Structure, regulation and selective inhibition. Trends Pharmacol Sci 17:294-298, 1996
44. Souness JE, Rao S: Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227-236, 1997
45. Swinnen JV, Joseph DR, Conti M: The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc Natl Acad Sci USA 86:8197-8201, 1989
46. Bolger GB, Erdogan S, Jones RE, Loughney K, Scotland G, Hoffmann R, Wilkinson I, Farrell C, Houslay MD: Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem J 328:539-548, 1997
47. Sette C, Conti M: Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase: Involvement of serine 54 in the enzyme activation. J Biol Chem 271:16526-16534, 1996
48. Nemoz G, Sette C, Conti M: Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Mol Pharmacol 51:242-249, 1997
49. Gillespie PG: Phosphodiesterases in visual transduction by rods and cones, in Structure, Regulation and Drug Action, edited by Beavo J, Houslay MD, New York, John Wiley & Sons, 1990, pp 163-184
50. Michaeli T, Bloom TJ, Martins T, Loughney K, Ferguson K, Riggs M, Rodgers L, Beavo JA, Wigler M: Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem 268:12925-12932, 1993
51. Bloom TJ, Beavo JA: Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 93:14188-14192, 1996
52. Han P, Zhu X, Michaeli T: Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 272:16152-16157, 1997
53. Fisher DA, Smith JF, Pillar JS: Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 246:570-577, 1998
54. Soderling SH, Bayuga SJ, Beavo JA: Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc Natl Acad Sci USA 95:8991-8996, 1998
55. Soderling SH, Bayuga SJ, Beavo JA: Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553-15558, 1998
56. Fisher DA, Smith JF, Pillar JS, St. Denis SH, Cheng JB: Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 273:15559-15564, 1998
57. Bentley JK, Beavo JA: Regulation and function of cyclic nucleotides. Curr Opin Cell Biol 4:233-240, 1992
58. Francis SH, Colbran JL, McAllister-Lucas LM, Corbin JD: Zinc interactions and conserved motifs of the cGMP-binding cGMP-specific phosphodiesterase suggest that it is a zinc hydrolase. J Biol Chem 269:22477-22480, 1994
59. Dousa T, Rychlik I: The metabolism of adenosine 3′,5′-cyclic phosphate. II. Some properties of adenosine 3′,5′-cyclic phosphate phosphodiesterase from the rat kidney. Biochim Biophys Acta 204:10-17, 1970
60. A cyclic AMP-specific phosphodiesterase expressed in yeast. Biochem J 304:407-415, 1994
61. Cloutier JF, Chow LM, Veillette A: Requirement of the SH3 and SH2 domains for the inhibitory function of tyrosine protein kinase p50csk in T lymphocytes. Mol Cell Biol 15:5937-5944, 1995
62. Leusen JHW, Verhoeven AJ, Roos D: Interactions between the components of the human NADPH oxidase: Intrigues in the phox family. J Lab Clin Med 128:461-476, 1996
63. Shakur Y, Wilson M, Pooley L, Lobban M, Griffiths SL, Campbell AM, Beattie J, Daly C, Houslay MD: Identification and characterization of the type-IV A cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem J 306:801-809, 1995
64. Tamai KT, Monaco L, Nantel F, Zazopoulos E, Sassone-Corsi P: Coupling signaling pathways to transcriptional control: Nuclear factors responsive to cAMP. Recent Prog Horm Res 52:121-139, 1997
65. MacKenzie SJ, Yarwood SJ, Peden AH, Bolger GB, Vernon RJ, Houslay MD: Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadiposytes. Proc Natl Acad Sci USA 95:3549-3554, 1998
66. Matousovic K, Grande JP, Chini CCS, Chini EN, Dousa TP: Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress proliferation of rat mesangial cells. J Clin Invest 96:401-410, 1995
67. Houslay MD: The N-terminal alternately spliced regions of PDE4A cAMP-specific phosphodiesterases determine intracellular targeting and regulation of catalytic activity. Biochem Soc Trans 24:980-986, 1996
68. Fox JE: Platelet activation: New aspects. Haemostasis 26:102-131, 1996
69. Walker H, Beard M, Houslay MD, Dousa TP: Isoforms of cyclic-3′,5′-nucleotide phosphodiesterase type 4 (PDE4) in mesangial cells (MC) that interact with SH3 and SH2 domains: Potential signaling components in pathways that regulate generation of reactive oxygen species (ROS). (abstract). J Am Soc Nephrol 9:432, 1998
70. Reinhardt RR, Chin E, Zhou J, Taira M, Murata T, Manganiello VC, Bondy CA: Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J Clin Invest 95:1528-1538, 1995
71. Polli JW, Kincaid RL: Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J Neurosci 14:1251-1261, 1994
72. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, Wendel A, Church MK, Shute JK: Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 25:625-633, 1995
73. Tenor H, Schudt C: Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods, in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 21-40
74. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Drebs EG, Beavo JA: Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100:2611-2621
75. Bode DC, Kanter JR, Brunton LL: Cellular distribution of phosphodiesterase isoforms in rat cardiac tissue. Circ Res 68:1070-1079, 1991
76. Levitzki A: Targeting signal transduction for disease therapy. Curr Opin Cell Biol 8:239-244, 1996
77. Mèry P-V, Pavoine C, Pecker F, Fischmeister R: EHNA as an inhibitor of PDE2: A pharmacological and biochemical study in cardiac myocytes, in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 81-88
78. Rivet-Bastide M, Vandecasteele G, Hatem S, Verde I, Bernardeau A, Mercadier JJ, Fischmeister R: cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. J Clin Invest 99:2710-2718, 1997
79. Dickinson NT, Jang EK, Haslam RJ: Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: Effects on platelet aggregation. Biochem J 323:371-377, 1997
80. Beltman J, Becker DE, Butt E, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA: Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: Topology of the catalytic domains. Mol Pharmacol 47:330-339, 1995
81. Take S, Matsutani M, Ueda H, Hamaguchi H, Konishi H, Baba Y, Kawaratani H, Sugiura T, Iwasaka T, Inada M: Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 79:1097-1099, 1997
82. Shipley JB, Tolman D, Hastillo A, Hess ML: Milrinone: Basic and clinical pharmacology and acute and chronic management. Am J Med Sci 311:286-291, 1996
83. m cyclic AMP phosphodiesterases: A family of highly related enzymes, in Structure, Regulation and Drug Action, edited by Beavo J, Houslay MD, New York, John Wiley & Sons, 1990, pp 245-266
84. Erdogan S, Houslay MD: Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant. Biochem J 321:165-175, 1997
85. 2. J Biol Chem 270:23598-23604, 1995
86. Alvarez R, Sette C, Yang D, Eglen RM, Wilhelm R, Shelton ER, Conti M: Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol Pharmacol 48:616-622, 1995
87. Alvarez R, Daniels DV, Shelton ER, Baecker PA, Fong TAT, Devens B, Wilhelm R, Eglen RM, Conti M: An isoform-selective inhibitor of cyclic AMP-specific phosphodiesterase (PDE4) with anti-inflammatory properties, in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 161-171
88. Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, Houslay MD: The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344, 1996
89. Sette C, Iona S, Conti M: The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem 269:9245-9252, 1994
90. Palfreyman MN, Souness JE: Phosphodiesterase type IV inhibitors. Prog Med Chem 33:1-52, 1996
91. Stafford JA, Feldman PL: Chronic pulmonary inflammation and other therapeutic applications of PDE IV inhibitors, in Annual Reports in Medicinal Chemistry (vol 31), edited by Bristol JA, New York, Academic Press, 1996, pp 71-80
92. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG: Phosphodiesterase (PDE) 4 inhibitors: Anti-inflammatory drugs of the future? Trends Pharmacol Sci 18:164-171, 1997
93. Thomas MK, Francis SH, Corbin JD: Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 265:14971-14978, 1990
94. Burns F, Pyne NJ: Interaction of the catalytic subunit of protein kinase A with the lung type V cyclic GMP phosphodiesterase: Modulation of non-catalytic binding sites. Biochem Biophys Res Commun 189:1389-1396, 1992
95. Silver PJ: Inhibition of phosphodiesterase isoenzymes and cell function by selective PDE5 inhibitors, in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 127-134
96. Saeki T, Adachi H, Takase Y, Yoshitake S, Souda S, Saito I: A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. J Pharmacol Exp Ther 272:825-831, 1995
97. Boolell M, Allen MJ, Ballard SA, Gepi-attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Intracellular J Impot Res 8:47-52, 1996
98. Coste H, Grondin P: Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem Pharmacol 50:1577-1585, 1995
99. Ichimura M, Kase H: A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem Biophys Res Commun 193:985-990, 1993
100. Vemulapalli S, Watkins RW, Chintala M, Davis H, Ahn HS, Fawzi A, Tulshian D, Chiu P, Chatterjee M, Lin CC, Sybertz EJ: Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol 28:862-869, 1996
101. Kariya T, Dage RC: Tissue distribution and selective inhibition of subtypes of high affinity cAMP phosphodiesterase. Biochem Pharmacol 37:3267-3270, 1988
102. Rassier ME, McIntyre SJ, Yamaki M, Takeda S, Lin J-T, Dousa TP: Isozymes of cyclic-3′,5′-nucleotide phosphodiesterases in renal epithelial LLCPK, cells. Kidney Int 41:88-99, 1992
103. Thompson WJ: Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function. Pharmacol Ther 51:13-33, 1991
104. Dent G, Rabe KF: Effects of theophylline and non-selective xanthine derivatives on PDE isoenzymes and cellular function, in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 41-64
105. 2+ release. Am J Physiol 271:C1007-C1024, 1996
106. Wells JN, Wu YJ, Baird CE, Hardman JG: Phosphodiesterases from porcine coronary arteries: Inhibition of separated forms by xanthines, papaverine, and cyclic nucleotides. Mol Pharmacol 11:775-783, 1975
107. Lavan BE, Lakey T, Houslay MD: Resolution of soluble cyclic nucleotide phosphodiesterase isoenzymes, from liver and hepatocytes, identifies a novel IBMX-insensitive form. Biochem Pharmacol 38:4123-4136, 1989
108. Robison GA, Butcher RW, Sutherland EW: Cyclic AMP and hormone action, in Cyclic AMP, edited by Robison GA, Butcher RW, Sutherland EW, New York, Academic Press, 1971, pp 17-47
109. Hindmarch I, Fuchs HH, Erzigkeit H: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol 6:31-43, 1991
110. Nicholson CD: Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101:147-159, 1990
111. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S: Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone: Suppression of natural killer cell activity and tumor necrosis factor-alpha production. J Clin Invest 94:1212-1217, 1994
112. Carson P: Pharmacologic treatment of congestive heart failure. Clin Cardiol 19:271-277, 1996
113. Ochiai M, Isshiki T, Takeshita S, Eto K, Toyoizumi H, Sato T, Miyashita H: Use of cilostazol, a novel antiplatelet agent, in a post-Palmaz-Schatz stenting regimen. Am J Cardiol 79:1471-1474, 1997
114. Kambayashi J, Watase M, Kawasaki T, Shiba E, Sakon M, Mori T, Isaka Y, Kimura K, Kamada T: Phosphodiesterase inhibitors as antiplatelet agents in vascular surgery, in Advances in Second Messenger and Phosphoprotein Research (vol 5), edited by Strada SJ, Hidaka H, New York, Raven Press, 1992, pp 383-393
115. Wagner RS, Smith CJ, Taylor AM, Rhoades RA: Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries. J Pharmacol Exp Ther 282:1650-1657, 1997
116. Ono S, Ueda S, Sakuma T, Tanita T, Koika K, Fujimura S: Relaxation of human isolated pulmonary arteries by amrinone. J Cardiovasc Surg 37:177-181, 1996
117. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, Dousa TP: Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV. J Clin Invest 98:262-270, 1996
118. Tam F, Smith WK, Morel D, Agarwal S, Pusey CD: Type IV phosphodiesterase inhibitor is effective in both prevention and treatment of progressive experimental glomerulonephritis. (abstract) J Am Soc Nephrol 7:1722, 1996
119. Overstreet DH, Double K, Schiller GD: Antidepressant effects of rolipram in a genetic animal model of depression: Cholinergic supersensitivity and weight gain. Pharmacol Biochem Behav 34:691-696, 1989
120. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H: Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 238:2-6, 1988
121. 2-adrenoceptor agonists in asthma. Trends Pharmacol Sci 17:331-336, 1996
122. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR JR, Kirby DS, Weiner ES: Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 107:51-56, 1996
123. Hanifin JM, Chan SC: Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 105:84S-88S, 1995
124. Sommer N, Loschmann PA, Northoff GH, Weller M, Steinbrecher A, Steinbach JP, Lichtenfels R, Meyermann R, Riethmuller A, Fontana A: The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Med 1:244-248, 1995
125. Genain CP, Roberts T, Davis RL, Nguyen M-H, Uccelli A, Faulds D, Li Y, Hedgpeth J, Hauser SL: Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA 92:3601-3605, 1995
126. Suttorp N, Weber U, Welsch T, Schudt C: Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 91:1421-1428, 1993
127. Pinsky D, Oz M, Liao H, Morris S, Brett J, Sciacca R, Karakurum M, Van Lookeren CM, Platt J, Nowygrod R: Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model. J Clin Invest 92:2994-3002, 1993
128. Naka Y, Roy DK, Liao H, Chowdhury NC, Michler RE, Oz MC, Pinsky DJ: cAMP-mediated vascular protection in an orthotopic rat lung transplant model: Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ Res 79:773-783, 1996
129. Dousa MK, Moore SB, Ploeger NA, DeGoey SR, Dousa TP: Antagonists of cyclic nucleotide phosphodiesterase (PDE) isozymes PDE3, PDE4 suppress lymphoblastic response to HLA class II alloantigens: A potential novel approach to preventing allograft rejections? Clin Nephrol 47:187-189, 1997
130. Takahashi T, Kanda T, Inoue M, Suzuki T, Kobayashi I, Kodama K, Nagai R: A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci 59:PL371-377, 1996
131. Braner DA, Fineman JR, Chang R, Soifer SJ: M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 264:H252-H258, 1993
132. Lee EYW, Humphreys MH: Phosphodiesterase activity as a mediator of renal resistance to ANP in pathological salt retention. Am J Physiol (Renal Fluid Electrol Physiol) 40:F3-F6, 1996
133. Valentin J-P, Ying W-Z, Sechi LA, Ling K-T, Qiu C, Couser WG, Humphreys MH: Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rats with Heymann nephritis. J Am Soc Nephrol 7:582-593, 1996
134. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ: Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 78:257-261, 1996
135. Pinsky DJ, Naka Y, Chowdhury NC, Liao H, Oz MC, Michler RE, Kubaszewski E, Malinski T, Stern DM: The nitric oxide/ cyclic GMP pathway in organ transplantation: Critical role in successful lung preservation. Proc Natl Acad Sci USA 91:12086-12090, 1994
136. Ahn HS, Crim W, Pitts B, Sybertz EJ: Calcium-calmodulin-stimulated and cyclic GMP-specific phosphodiesterases: Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels. Adv Second Messenger Phosphoprotein Res 25:271-288, 1992
137. Hatzelmann A, Engelstätter R, Morley J, Mazzoni L: Enzymatic and functional aspects of dual-selective PDE3/4 inhibitors, in Phosphodiesterase Inhibitors, edited by Schudt C, Dent G, Rabe KF, New York, Academic Press, 1996, pp 147-160
138. Schudt C, Winder S, Müller B, Ukena D: Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem Pharmacol 42:153-162, 1991
139. Masuoka H, Ito M, Sugioka M, Kozeki H, Konishi T, Tanaka T, Nakano T: Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their response to vesnarinone, a new cardiotonic agent. Biochem Biophys Res Commun 190:412-417, 1993
140. Sharma RK, Kalra J: Ginsenosides are potent and selective inhibitors of some calmodulin-dependent phosphodiesterase isozymes. Biochem 18:4975-4978, 1993
141. Chini CCS, Grande JP, Chini EN, Dousa TP: Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4: Regulation of superoxidation and mitogenesis. J Biol Chem 272:9854-9859, 1997
142. Butcher RW, Sutherland EW: Adenosine 3′,5′-phosphate in biological materials. J Biol Chem 237:1244-1250, 1962
143. Dousa TP, Rychlik I: Adenyl cyclase and adenosine 3′,5′-cyclic phosphate phosphodiesterase in the receptor tissues of neurohypophyseal hormones. Life Sci 7:1039-1044, 1968
144. Thompson WJ, Epstein PM, Strada SJ: Purification and characterization of high affinity cyclic AMP phosphodiesterase from dog kidney. Biochemistry 18:5228-5237, 1979
145. Morel F, Imbert-Teboul M, Chabardes D: Distribution of hormone-dependent adenylate cyclase in the nephron and its physiological significance. Annu Rev Physiol 43:569-581, 1981
146. Dousa TP, Valtin H: Cellular action of antidiuretic hormone in mice with inherited vasopressin-resistant urinary concentrating defects. J Clin Invest 54:753-762, 1974
147. Jackson BA, Edwards RM, Valtin H, Dousa TP: Cellular action of vasopressin in medullary tubules in mice with hereditary nephrogenic diabetes insipidus. J Clin Invest 66:110-122, 1980
148. Homma S, Gapstur SM, Coffey A, Valtin H, Dousa TP: Role of cAM-phosphodiesterase isozymes in the pathogenesis of murine nephrogenic diabetes insipidus. Am J Physiol 261:F345-F353, 1991
149. Dousa TP, Homma S, Valtin H, Coffey A: Cellular pathogenesis of nephrogenic diabetes insipidus in mice, in Recent Progress in Posterior Pituitary Hormones, edited by Yoshida S, Share L, Basle, Elsevier Science, 1988, pp 321-326
150. Takeda S, Lin CT, Morgano PG, McIntyre SJ, Dousa TP: High activity of low-Michaelis-Menten constant 3′,5′-cyclic adenosine monophosphate-phosphodiesterase isozymes in renal inner medulla of mice with hereditary nephrogenic diabetes insipidus. Endocrinology 129:287-294, 1991
151. Torres VE, Hui YSF, Shah SV, Northrup TE, Dousa TP: Cyclic nucleotide phosphodiesterases in glomeruli of rat renal cortex. Kidney Int 14:444-451, 1978
152. Matousovic K, Tsuboi Y, Walker H, Grande JP, Dousa TP: Inhibitors of cyclic nucleotide phosphodiesterase isozymes block renal tubular cell proliferation induced by folic acid. J Lab Clin Med 130:487-495, 1997
153. Chini CS, Chini EN, Williams JM, Matousovic K, Dousa TP: Formation of reactive oxygen metabolites in glomeruli is suppressed by inhibition of cAMP phosphodiesterase isozyme type-IV. Kidney Int 46:28-36, 1994
154. Dousa TP: Glomerular metabolism, in The Kidney: Physiology and Pathophysiology, edited by Seldin DW, Giebisch G, New York, Raven Press, 1985, pp 645-667
155. Chini CCS, Grande JP, Thompson MA, Walker HJ, Dousa TP: Isoenzymes of cyclic-3′,5′-nucleotide phosphodiesterases (PDE) in rat glomerular epithelial cells (GEC) and mesangial cells (MC). (abstract) FASEB J 8:A83, 1994
156. Valentin J-P, Qiu C, Muldowney WP, Ying W-Z, Gardner DC, Humphreys MH: Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 90:1302-1312, 1992
157. Jackson BA, Edwards RM, Dousa TP: Measurements of cyclic AMP and cyclic GMP phosphodiesterase activity in isolated tubular segments. Kidney Int 18:512-518, 1980
158. 2. Am J Physiol 240:F311-F318, 1981
159. Kim JK, Jackson BA, Edwards RM, Dousa TP: Effect of potassium depletion on the vasopressin-sensitive cyclic AMP system in rat outer medullary tubules. J Lab Clin Med 99:29-38, 1982
160. Christensen S, Kusano E, Yusufi ANK, Murayama N, Dousa TP: Pathogenesis of nephrogenic diabetes insipidus due to chronic administration of lithium in rats. J Clin Invest 75:1869-1879, 1985
161. Kusano E, Braun-Werness JL, Vick DJ, Keller MJ, Dousa TP: Chlorpropamide action on renal concentrating mechanism in rats with hypothalamic diabetes insipidus. J Clin Invest 72:1298-1313, 1983
162. Kusano E, Murayama N, Werness JL, Christensen S, Homma S, Yusufi ANK, Dousa TP: Effects of calcium on the vasopressin-sensitive cAMP metabolism in medullary tubules. Am J Physiol 249:F956-F966, 1985
163. Kiebzak GM, Yusufi ANK, Kusano E, Braun-Werness JL, Dousa TP: ATP and cAMP system in the in vitro response of the microdissected cortical tubules to PTH. Am J Physiol 248:F152-F159, 1985
164. Jackson BA, Braun JL, Kusano E, Dousa TP: Concentrating defect in the adrenalectomized rat: Abnormal vasopressin-sensitive cyclic adenosine monophosphate metabolism in the papillary collecting duct. J Clin Invest 72:997-1004, 1983
165. Kusano E, Kiebzak GM, Dousa TP: Cyclic AMP phosphodiesterase (cDPR-PDIE) activity in various nephron segments of mouse and rat kidney. (abstract) Clin Res 30:454, 1982
166. Kriz W, Bankir L, Bulger RE, Burg MB, Goncharevskaya OA, Imai M, Kaissling B: A standard nomenclature for structures of the kidney. Am J Physiol 254:F1-F8, 1988
167. Kusano E, Kiebzak GM, Jackson BA, Braun J, Dousa TP: Low cyclic AMP-phosphodiesterase (cAMP-PDIE) activity in the proximal convoluted tubules of the X-linked hypophosphatemic (HYP) mouse. (abstract) Kidney Int 21:163, 1982
168. Kempson SA, Kim JK, Northrup TE, Knox FG, Dousa TP: Alkaline phosphatase in adaptation to low dietary phosphate intake. Am J Physiol 237:E465-E473, 1979
169. Berndt TJ, Homma S, Yusufi ANK, Dousa TP, Knox FG: Effect of phosphate deprivation on enzymes of cAMP metabolism in rat proximal convoluted and proximal straight tubules. Renal Physiol Biochem 13:241-247, 1990
170. Tetsuka T, Kusano E, Takeda S, Homma S, Yoshida I, Ando Y, Asano Y: Activation of protein kinase C stimulates cAMP phosphodiesterase in rat renal collecting tubule. Am J Physiol 268:F808-F814, 1995
171. Le Goas F, Amiel C, Friedlander G: Protein kinase C modulates cAMP content in proximal tubular cells: Role of phosphodiesterase inhibition. Am J Physiol 261:F587-F592, 1991
172. 2+-ATPase pump in the rat kidney. Am J Physiol 263:F7-F14, 1992
173. Nonoguchi H, Knepper MA, Manganiello VC: Effects of atrial natriuretic factor on cyclic guanosine monophosphate and cyclic adenosine monophosphate accumulation in microdissected nephron segments from rats. J Clin Invest 79:500-507, 1987
174. Ludvig N, Burmeister V, Jobe PC, Kincaid RL: Electron microscopic immunocytochemical evidence that the calmodulin-dependent cyclic nucleotide phosphodiesterase is localized predominantly at postsynaptic sites in the rat brain. Neuroscience 44: 491-500, 1991
175. Schoeffter P, Lugnier C, Travo C, Sroclet J-C: A comparison of cyclic AMP signaling system in rat aortic myocytes in primary culture and aorta. Lab Invest 61:177-182, 1989
176. 1 cells caused by overexpression of cAMP-phosphodiesterase type-IV. Kidney Int 43:1286-1297, 1993
177. 1 cells in vitro. (abstract) J Am Soc Nephrol 3:510, 1992
178. Dousa TP: Cyclic-3′,5′-nucleotide phosphodiesterases in the cAMP-mediated actions of vasopressin. Semin Nephrol 14:333-340, 1994
179. 1 receptors in opossum kidney cells. J Biol Chem 268:14757-14763, 1993
180. Yamaki M, McIntyre S, Rassier ME, Schwaftz JH, Dousa TP: Cyclic-3′,5′-nucleotide diesterases in dynamics of cAMP and cGMP in rat collecting duct cells. Am J Physiol 262:F957-F964, 1992
181. Ahn HS, Foster M, Arik L, Boykow G, Foster C: Cyclic nucleotide phosphodiesterase isozymes in rat mesangial cells. Eur J Pharmacol 289:49-57, 1995
182. Kawaguchi M, Kawashima F, Ohshima K, Kawaguchi S, Wada H: Immunocytochemical characterization and identification of SGE1, a rat glomerular epithelial cell line. Pathobiology 62:283-291, 1994
183. Souness JE, Diocee BK, Martin W, Moodie SA: Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Biochem J 266:127-132, 1990
184. Lugnier C, Schini VB: Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem Pharmacol 39:75-84, 1990
185. Sechi LA, Valentin JP, Griffin CA, Lee E, Bartoli E, Humphreys MH, Schambelan M: Receptors for atrial natriuretic peptide are decreased in the kidney of rats with streptozotocin-induced diabetes mellitus. J Clin Invest 95:2451-2457, 1995
186. Kalinowski L, Szczepanska-Konkel M, Pawelczyk T, Bizon D, Angielski S: Inhibition of cGMP-phosphodiesterase restores the glomerular effects of atrial natriuretic factor in low sodium diet rats. Renal Physiol Biochem 18:254-266, 1995
187. Kalinowski L, Szczepanska-Konkel M, Jankowski M, Angielski S: Modulation by low sodium intake of glomerular response to cicletanine and atrial natriuretic factor. Br J Pharmacol 121: 635-642, 1997
188. Supaporn T, Sandberg SM, Borgeson DD, Heublein DM, Luchner A, Wei C-M, Dousa TP, Burnett JC Jr: Blunted cGMP response to agonists and enhanced glomerular cyclic 3′,5′-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int 50:1718-1725, 1996
189. Norling LL, Thornhill BA, Chevalier RL: Abnormal glomerular response to atrial natriuretic peptide in rats with aortocaval fistulas. J Am Soc Nephrol 7:1038-1044, 1996
190. McDowell KA, Chevalier RL, Thornhill BA, Norling LL: Unilateral ureteral obstruction increases glomerular soluble guanylyl cyclase activity. J Am Soc Nephrol 6:1498-1503, 1995
191. Haneda M, Kikkawa R, Maeda S, Togawa M, Koya D, Horide N, Kajiwara N, Shigeta Y: Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int 40:188-194, 1991
192. Kurtz A, Götz K-H, Hamann M, Wagner C: Stimulation of renin secretion by nitric oxide is mediated by phosphodiesterase 3. Proc Natl Acad Sci USA 95:4743-4747, 1998
193. Chiu N, Park I, Reid IA: Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram. J Pharmacol Exp Ther 276:1073-1077, 1996
194. Shah SW: Oxidant mechanisms in glomerulonephritis. Semin Nephrol 11:320-326, 1991
195. Shah SW: Light emission by isolated rat glomeruli in response to phorbol myristate acetate. J Lab Clin Med 98:46-57, 1981
196. Wright CD, Kuipers PJ, Kobylarz-Singer D, Devall LJ, Klinkefus BA, Weishaar RE: Differential inhibition of human neutrophil functions: Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem Pharmacol 40:699-707, 1990
197. Appel RG: Growth-regulatory properties of atrial natriuretic factor. Am J Physiol 262:F911-F918, 1992
198. Johnson RJ: The glomerular response to injury: Progression or resolution? Kidney Int 45:1769-1782, 1994
199. Ryan WL, Heidrick ML: Role of cyclic nucleotides in cancer, in Advances in Cyclic Nucleotide Research (vol 4), edited by Greengard P, Robison GA, New York, Raven, 1974, pp 81-116
200. Cano E, Mahadevan LC: Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 20:117-122, 1995
201. Bokemeyer D, Sorokin A, Dunn MJ: Multiple intracellular MAP kinase signaling cascades. Kidney Int 49:1187-1198, 1996
202. Sugimoto T, Haneda M, Togawa M, Isono M, Shikano T, Araki S, Nakagawa T, Kashiwagi A, Guan KL, Kikkawa R: Atrial natriuretic peptide induces the expression of MKP-1, a mitogen activated protein kinase phosphatase, in glomerular mesangial cells. J Biol Chem 271:544-547, 1996
203. Häfner S, Adler HS, Mischak H, Janosch PA, Heidecker G, Wolfman A, Pippig S, Lohse M, Uefing M, Kolch W: Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol 14:6696-
204. Mischak H, Seitz T, Janosch P, Eulitz M, Steen H, Schellerer M, Philipp A, Kolch W: Negative regulation of Raf-1 by phosphorylation of serine 621. Mol Cell Biol 16:5409-5418, 1996
205. Marx J: Two major signal pathways linked. Science 262:988-989, 1993
206. Huang C-YF, Ferrell JE Jr: Ultrasensitivity in the mitogen activated protein kinase cascade. Proc Natl Acad Sci USA 93: 10078-10083, 1996
207. Haneda M, Araki S, Sugimoto T, Togawa M, Koya D, Kikkawa R: Differential inhibition of mesangial MAP kinase cascade by cyclic nucleotides. Kidney Int 50:384-391, 1996
208. Tsuboi Y, Shankland SJ, Grande JP, Walker HJ, Johnson RJ, Dousa TP: Antagonist of cAMP phosphodiesterase isozyme PDE-III blocks development of proteinuria, mesangial cell (MC) proliferation and phenotypic transformation in mesangioproliferative glomerulonephritis (MSGN) elicited by antithymic serum (ATS) in rats. (abstract) J Am Soc Nephrol 7:1724, 1996
209. Bokemeyer D, Guglielmi KE, McGinty A, Sorokin A, Lianos EA, Dunn MJ: Activation of extracellular signal-regulated kinase in proliferative glomerulonephritis in rats. J Clin Invest 100:582-588, 1997
210. Dousa TP, Shah SV, Abboud HE: Potential role of cyclic nucleotides in glomerular pathophysiology, in Advances Cyclic Nucleic Research, edited by Hamet P, Sands H, New York, Raven Press, 1980, pp 285-299
211. Kohno M, Yokokawa K, Yasunari K, Kano H, Horio T, Takeda T: Stimulation of cyclic adenosine monophosphate formation by the novel vasorelaxant peptide adrenomedullin in cultured rat mesangial cells. Metabolism 44:10-12, 1995
212. Chini EN, Chini CCS, Bolliger C, Jougasaki M, Grande, JP, Burnett JC Jr, Dousa TP: Cytoprotective effects of adrenomedullin in glomerular cell injury: Central role of cAMP signaling pathway. Kidney Int 52:917-925, 1997
213. Schade FU, Schudt C: The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur J Pharmacol 230:9-14, 1993
214. Seldon PM, Barnes PJ, Meja K, Giembycz MA: Suppression of lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: Interaction with stimulants of adenylyl cyclase. Mol Pharmacol 48:747-757, 1995
215. Semmler J, Wachtel H, Endres S: The specific type-IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharmacol 15:409-413, 1993
216. Nyman U, Müssener Å, Larsson E, Lorentzen J, Klareskog L: Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram. Clin Exp Immunol 108:415-419, 1997
217. Sekut L, Yarnall D, Stimpson SA, Noel LS, Bateman-Fite R, Clark RL, Brackeen MF, Menius JA, Connolly KM: Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clin Exp Immunol 100:126-132, 1995
218. Coffey A, O'Sullivan DJ, Homma S, Dousa TP, Valtin H: Induction of intramembranous particle clusters in mice with nephrogenic diabetes insipidus. Am J Physiol 261:F640-F646, 1991
219. Moses AM, Scheinman SJ: Hereditary vasopressin resistance in man and mouse. Ann NY Acad Sci 689:233-249, 1993
220. Ni X, Cheng Y, Cao L, Gardner DG, Humphreys MH: Mechanisms contributing to renal resistance to atrial natriuretic peptide in rats with common bile-duct ligation. J Am Soc Nephrol 7:2110-2118, 1996
221. Threlfall G: Cell proliferation in the rat kidney induced by folic acid. Cell Tissue Kinet 1:383-392, 1968
222. Begany DP, Carcillo JA, Herzer WA, Mi Z, Jackson EK: Inhibition of type IV phosphodiesterase by Ro 20-1724 attenuates endotoxin-induced acute renal failure. J Pharmacol Exp Ther 278:37-41, 1996
223. Carcillo JA, Herzer WA, Mi Z, Thomas NJ, Jackson EK: Treatment with the type IV phosphodiesterase inhibitor Ro 20-1724 protects renal and mesenteric blood flow in endotoxemic rats treated with norepinephrine. J Pharmacol Exp Ther 279: 1197-1204, 1996
224. Stadnyk AW: Cytokine production by epithelial cells. FASEB J 8:1041-1047, 1994
225. Eckly-Michel A, Martin V, Lugnier C: Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation. Br J Pharmacol 122:158-164, 1997
226. Guan Z, Miller SB, Greenwald JE: Zaprinast accelerates recovery from established acute renal failure in the rat. Kidney Int 47:1569-1575, 1995
227. Harris AL, Lemp BM, Bentley RG, Perrone MH, Hamel LT, Silver PJ: Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther 249:394-400, 1989
228. Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ: Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30:703-709, 1997
229. Grantham JJ: Renal cell proliferation and the two faces of cyclic adenosine monophosphate. J Lab Clin Med 130:459-460, 1997
230. Yan SF, Ogawa S, Stern DM, Pinsky DJ: Hypoxia-induced modulation of endothelial cell properties: Regulation of barrier function and expression of interleukin-6. Kidney Int 51:419-425, 1997
231. Pinsky DJ, Yan SF, Lawson C, Naka Y, Chen JX, Connolly ES Jr, Stern DM: Hypoxia and modification of the endothelium: Implications for regulation of vascular homeostatic properties. Semin Cell Biol 6:283-294, 1995
232. Hirozane T, Matsumori A, Furukawa Y, Matsui S, Matoba Y, Sasayama S: Prolongation of murine cardiac allograft survival with vesnarinone. J Mol Cell Cardiol 29:67-76, 1997